Kanabo Strengthens Operations Team, Welcoming Michal Ben Moshe as General Manager
March 26 2021 - 02:00AM
Business Wire
Kanabo Group Plc is thrilled to announce the new appointment of
Michal Ben Moshe as General Manager. Michal will be tasked with
operational execution of the Company’s business plan, overseeing
company goals and curating an agile team to support and enable its
growth. Michal will report directly to Kanabo’s CEO, Avihu
Tamir.
Michal was chosen specifically for the 20 years of leadership
experience that she brings having worked as the Senior Director of
Finance & Commercial Affairs at S.L.E Ltd., one of the leading
providers of logistic and operations in the healthcare field in
Israel and a part of Teva Group (the largest generic pharmaceutical
manufacturer worldwide). Michal’s in-depth knowledge of commercial
activities, finance, and operations will enable her to fulfill
Kanabo’s business plan and objectives.
Michal has a proven track record in development and growth
implementation strategies, having met company goals with exemplary
results. While working at S.L.E., she was able to successfully
increase revenues and profit and conducted improvement of processes
that resulted in a significant improvement in cash flow. Further
achievements include strengthening relationships with global
stakeholders and positioning S.L.E on an international scale,
having led the company to a two-time recipient of the LogiPharma
Award for pharmaceutical supply chain leaders.
Michal Ben Moshe commented: “I'm excited to join Kanabo’s
team, and have full confidence in the company’s success, and its
ability to contribute to the quality of life improvement for
thousands of patients.
Avihu Tamir, CEO Kanabo said: “We couldn’t be more
thrilled to have Michal join our team. The additional management
bandwidth that she provides will enable us to accelerate the
evaluation and roll-out of new market entries, distributor network
expansion and strategic partnerships.”
Kanabo focuses on the distribution of cannabis-derived products
for medical patients, and non-THC products for CBD consumers. They
have conducted extensive R&D in order to develop high-quality
cannabis oil formulas, innovative medical-grade vaporisers, and
various non-smoking consumption solutions. The company’s clinical
and validation activities, including safety and efficiency tests,
are conducted in Israel, an established leader in the cannabis
industry and they are ready to scale up to meet market demands,
projected sales, and revenues.
Kanabo’s goal is to lead the emerging markets of medical
cannabis in the medical vaporisation category, providing a healthy
alternative for many of the patients who are smoking cannabis
today. Kanabo is committed to a high standard, having a certified
medical device and an EU-GMP production, and has built great
partnerships, and will continue to build more.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210326005013/en/
Michelle Tamir, Marketing Manager press@kanabogroup.com Kanabo
Group, Plc Churchill House, 137-139 Brent Street, London, United
Kingdom, NW4 4DJ +(972)52-3173-633
Kanabo (LSE:KNB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kanabo (LSE:KNB)
Historical Stock Chart
From Mar 2023 to Mar 2024